Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, Ellen B. Nordal, Nadina Rubio-Pérez, Marija Jelusic, Jaime De Inocencio, Jelena Vojinovic, Nico M. Wulffraat, Patricia C. J. Bruijning-Verhagen, Nicolino Ruperto & Joost F. Swart
Collection published via figshare
Abstract Background Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data. Methods Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN...
No citations were reported. No usage information was reported.
https://doi.org/10.6084/m9.figshare.c.6299234.v1 Cite

Registration Year

  • 2022
    51

Resource Types

  • Collection
    51

Affiliations

  • University Medical Center Utrecht
    51
  • Utrecht University
    22
  • Leiden University Medical Center
    11
  • Erasmus MC
    8
  • Elisabeth-TweeSteden Ziekenhuis
    6
  • Radboud University Nijmegen Medical Centre
    6
  • University of Genoa
    4
  • Amphia Ziekenhuis
    4
  • St. Antonius Ziekenhuis
    4
  • McMaster University
    4

About DataCite

Services

Resources

Community